Compare WKEY & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | CGTX |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Switzerland | United States |
| Employees | 202 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 102.9M |
| IPO Year | N/A | 2021 |
| Metric | WKEY | CGTX |
|---|---|---|
| Price | $6.12 | $0.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.50 | $3.33 |
| AVG Volume (30 Days) | 48.3K | ★ 1.1M |
| Earning Date | 01-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.75 | $0.55 |
| 52 Week High | $19.80 | $3.83 |
| Indicator | WKEY | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 37.08 |
| Support Level | $5.32 | $0.55 |
| Resistance Level | $8.27 | $1.19 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 32.80 | 7.27 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).